Silencing the FOLR2 Gene Inhibits Cell Proliferation and Increases Apoptosis in the NCI-H1650 Non-Small Cell Lung Cancer Cell Line via Inhibition of AKT/Mammalian Target of Rapamycin (mTOR)/Ribosomal Protein S6 Kinase 1 (S6K1) Signaling

Background: The FOLR2 gene encodes folate receptor-beta (FR-beta), which is expressed by tumor-associated macrophages. The effects of FOLR2 gene expression in non-small cell lung cancer (NSCLC) remains unknown. This study aimed to investigate the effects of FOLR2 gene expression and gene silencing in human NSCLC cell lines and normal human bronchial epithelial (HBE) cells in vitro.

Material/Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot were performed to detect the expression of the FOLR2 gene, cell cycle and apoptosis-associated genes in normal HBE cells and the NSCLC cell lines, A549, NCI-H1299, NCI-H1650, and NCI-H460. Using small interfering RNA (siRNA), or silencing RNA, FOLR2 gene silencing was performed for NCI-H1650 cells. Cell counting kit-8 (CCK-8) was used to measure cell viability. Cell cycle and apoptosis were determined using flow cytometry. Western blot evaluated the expression of Akt, mTOR, and S6K1 signaling.

Results: Expression of the FOLR2 gene was increased in NSCLC cells compared with normal HBE cells. Silencing of the expression of the FOLR2 gene in NCI-H1650 cells reduced cell viability, increased cell apoptosis, and arrested cells in the G1 phase of the cell cycle, decreased the expression of cyclin D1, upregulated expression of cell cycle inhibitors, p21 and p27, upregulated the expression of Bax/Bcl-2, and inhibited phosphorylation of AKT, mTOR, and S6K1.

Conclusions: Silencing of the FOLR2 gene inhibited phosphorylation of AKT, mTOR, and S6K1, inhibited cell proliferation and increased apoptosis in the NCI-H1650 human NSCLC cell line.

MeSH Keywords: Apoptosis • Carcinoma, Non-Small-Cell Lung • Cell Cycle • Folate Receptor 2

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/911384
Background

In the United States (US), lung cancer is the most common type of malignancy, with almost 222,500 new cases diagnosed in 2017, resulting in 155,870 deaths within one year [1]. Worldwide, lung cancer remains a large health burden and cause of mortality. The two main histopathological types of lung cancer include the highly aggressive small cell lung cancer (SCLC), which has a high rate of recurrence [2]. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 80% of cases, and can be divided histologically into three types of NSCLC, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma [3].

The European Prospective Investigation into Cancer and Nutrition (EPIC) study reported that folic acid deficiency was associated with an increased risk of lung cancer [4]. Folic acid is only synthesized by microorganisms. Therefore, it needs to be obtained from the diet or dietary supplements. Folate deficiency is a secretory protein and FR-α is widely expressed in several tissues, including the kidney, breast, lung, and placenta [12,13]. The amino acid sequence for FR-α has 68% and 71% homology with FR-β and FR-γ, respectively. Although closely related in terms of its amino acid sequence, FR-β, encoded by the FOLR2 gene, has a different tissue distribution and cellular specificity and is associated with pro-inflammatory mononuclear phagocytes [14]. The FOLR2 gene has been shown to be expressed by malignant cells, including myelogenous leukemia cells, but has also been demonstrated to be mainly expressed by tumor-associated macrophages (TAMs) [15–17]. To our knowledge, no previous studies have been undertaken to investigate the effects of the expression of the FOLR2 gene, or its lack of expression, in human NSCLC cells.

Several molecular signaling pathways are now recognized to be involved in cell survival in human NSCLC, including the c-Jun N-terminal kinase (JNK) signaling pathway, the matrix metalloproteinase-2 (MMP-2) signaling pathway, the B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X (BAX) signaling pathway, the phosphatidylinositol 3-kinase (PI3K), AKT, nuclear factor (NF)-κB signaling pathway, and the solute carrier family 10 member 2 (SLC10A2), peroxisome proliferator-activated receptor gamma (PPARγ), phosphatase and tensin homolog (PTEN), mechanistic target of rapamycin (mTOR) signaling pathway [18–21]. Previously published studies have shown that activation of the AKT, mTOR, and mTOR substrate 56 kinase 1 (S6K1) signaling pathway can contribute to tumorigenesis, metastasis, and angiogenesis in several types of malignant tumors [22–25]. However, the AKT/mTOR/S6K1 signaling pathway in human NSCLC remains poorly understood.

Therefore, this study aimed to investigate the effects of FOLR2 gene expression and gene silencing on cell proliferation, the cell cycle, and apoptosis in human NSCLC cell lines and normal human bronchial epithelial (HBE) cells in vitro, including the components of the AKT/mTOR/S6K1 signaling pathway.

Material and Methods

Cell culture

Normal human bronchial epithelial cells (HBEs) and human non-small cell lung cancer (NSCLC) cell lines, A549, NCI-H1299, NCI-H1650, and NCI-H460, were obtained from Invitrogen (San Mateo, CA, USA). Cells were cultured in RPMI 1640 medium containing 20% fetal bovine serum (FBS) and incubated at 37°C and 5% CO₂. When cell confluence reached 80%, cells were digested with 0.25% trypsin and sub-cultured.

Cell transfection with small interfering RNA (siRNA), or silencing RNA, and grouping

The siRNA, or silencing RNA, for FOLR2 (si-FOLR2) and empty control plasmids were purchased from RiboBio (Guangzhou, China). NCI-H1650 cells were seeded in 6-well plates (1.0×10⁵) for 24 hours before transfection and divided into the following three groups: the control group (0.1% PBS), the NC group (treated with empty vector), and the siFOLR2 group (transfected with the small interfering RNA or siRNA plasmid).

Transient transfection was performed by Lipofectamine 2000 (Invitrogen, San Mateo, CA, USA) according to the manufacturer’s protocol. A total of 20 µM siRNA, control, NC, and 5 µL Lipofectamine 2000 was added to Opti-MEM® reduced serum medium and incubated at 25°C for 10 min. Lipofectamine 2000 was mixed into each group and cultured in Opti-MEM® RPMI 1640 medium. After 6 hours in culture, the fluid was changed back to RPMI 1640 medium containing 10% FBS.

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Cell viability assessed using cell counting kit-8 (CCK-8)

After transfection, NCI-H1650 cells were digested with 0.25% trypsin for 12, 24, and 48 hours. Cells were plated into 96-well plates at a seeding density of 1×10^4 cells per well and divided into three groups: the control group; the NC group; and the si-FOLR2 group. Then, 10 µL CCK-8 solution was added to cells for an additional 2 hours at 37°C. The optical density (OD) was measured at a wavelength of 450 nm (Thermo Fisher, MA, USA).

Flow cytometry

NCI-H1650 cells were digested with 0.25% trypsin and collected in 1.5 ml Eppendorf tubes and centrifuged at 3,500 rpm for 5 min. The apoptosis assay included washing the cells twice using washing buffer, and the suspension was cultured with an Annexin V-PE apoptosis kit and propidium iodide (PI) (Lianshu, Shanghai, China) in the dark at 25°C for 20min. Binding buffer was added to each well. Flow cytometry analyzed the cell samples within one hour.

Cell cycle was also studied using flow cytometry. Cells washed twice in PBS and fixed in ethanol at 4°C for 30 min, followed by centrifuging at 1,000 rpm for 5 min. Cells were washed and resuspended in PBS with RNase and PI (Lianshu, Shanghai, China) at 37°C for 30 min.

Quantitative real-time polymerase chain reaction (qRT-PCR)

Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure FOLR2 mRNA, cell cycle-related mRNA (for cyclin D1, p21, and p27), apoptosis-related mRNA (for BAX and Bcl-2) in the different cell groups. Total RNA was extracted from cultured cells with Trizol (Invitrogen, SanMateo, CA, USA) according to manufacturer’s instructions. Total RNA was reverse transcribed using the OrimeScript™ RT reagent kit (Lianshu, Shanghai, China) at 37°C for 30 min. cDNA was used for amplification by SYBR Fast qPCR Mix (Invitrogen, SanMateo, CA, USA) according to manufacturer’s instructions. Total RNA was reverse transcribed using the OrimeScript™ RT reagent kit (TaKaRa, Otsu, Shiga, Japan), performed at 42°C for 1 h and at 70°C for 10 min. cDNA was used for amplification by SYBR Fast qPCR Mix (Invitrogen, SanMateo, CA, USA). The PCR reaction consisted of the following cycles: an initial cycle at 95°C for 5 min; followed by 30 cycles at 94°C for another 30 seconds; then at 55°C for 30 seconds; and at 70°C for 45 seconds. The primer sequences are summarized in Table 1. Amplified products were electrophoresed in 1.2% agarose gels. The amount of RNA was calculated using the 2^-ΔΔCT method, and β-actin was used as an internal control [26].

Western blot

Total protein was extracted from cultured cells using lysis buffer and RIPA buffer added to each well, followed by centrifuging at 12,000×g for 10 min. The bicinechonic acid (BCA) assay was used as an internal control [26].

Proteins were detected by incubation of the gels with different primary antibodies, including: rabbit anti-Bcl-2 (1: 1,000) (ab32124; Abcam, Cambridge, MA, USA), anti-BAX (1: 1500) (ab32503; Abcam, Cambridge, MA, USA), anti-FOLR2 (1: 1000) (ab56067; Abcam, Cambridge, MA, USA), anti-cyclin D1 (1: 1000) (ab134175; Abcam, Cambridge, MA, USA), anti-p21 (1: 1000) (ab109520; Abcam, Cambridge, MA, USA), anti-p27 (1: 5000) (ab32034; Abcam, Cambridge, MA USA), anti-p21 (1: 1000) (ab2227; Abcam, Cambridge, MA, USA), anti-AKT (1: 1000) (SAB4500797; Sigma, USA), anti-p-AKT (1: 1000) (SAB4301414; Sigma, USA), anti-mTOR (1: 2000) (ab2732, 1: 2000, Abcam, USA), anti-p-mTOR (S2448, ab84400, 1: 2000, Abcam, USA), anti-S6K1 (ab32529; Abcam, Cambridge, MA, USA), anti-p-S6K1 (S2448) (1: 1000) (ab131436; Abcam, Cambridge, MA, USA). Following incubation with the primary antibody, the gels were washed with TBST, and then incubated with horse-radish peroxidase (HRP)-conjugated goat anti-rabbit IgG (Proteintech, Chicago, IL, USA) as secondary antibodies. The blot was visualized using an enhanced chemiluminescence (ECL) system (GE Healthcare, Chicago, IL, USA) to detect the bands. The density of the blots was measured using the Quantity One software version 2.4 (Bio-Rad, Hercules, CA, USA).

Statistical analysis

GraphPad Prism version 6.0 software was used for statistical analysis. All data were presented as the mean ± standard deviation.

Table 1. Primers used in qRT-PCR.

| Gene     | Primer | Sequence            |
|----------|--------|---------------------|
| FOLR2    | Forward| 5’-GCUCGUUCUUGUCUGUGCAGCAGG-3’ |
|          | Reverse| 5’-UCAGACAGCAAAAGCAGCAG-3’ |
| Cyclin D1| Forward| 5’-GGCAATTGCTGCTGGAAAGT-3’  |
|          | Reverse| 5’-GCAGACACCTTCAACAGCA-3’  |
| P21      | Forward| 5’-TGCGACAACCCTCCTCAGTAC-3’ |
|          | Reverse| 5’-TGGATGGCTTCTTGGAACAT-3’ |
| P27      | Forward| 5’-GCCACAAGAGCTTCGCAAGTACTG-3’ |
|          | Reverse| 5’-GCCACAAGAGCTTCGCAAGTACTG-3’ |
| Bcl-2    | Forward| 5’-TGCGAAGGCGGACCAGCTAC-3’ |
|          | Reverse| 5’-TGGATGGCTTCTTGGAACAT-3’ |
| β-actin  | Forward| 5’-CAGCGGAGGCAAGATGACTTTG-3’ |
|          | Reverse| 5’-TGGATGGCTTCTTGGAACAT-3’ |

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
deviation (SD). Differences were compared using one-way analysis of variance (ANOVA) following Tukey’s range test for multiple comparisons. A p-value <0.05 was considered to be statistically significant.

**Results**

Expression of FOLR2 mRNA and FOLR2 protein in normal human bronchial epithelial (HBE) cells and human non-small-cell lung cancer (NSCLC) cell lines

Normal human bronchial epithelial (HBE) cells and human non small-cell lung cancer (NSCLC) cell lines were studied for the expression of FOLR2 mRNA and protein levels. Almost all the NSCLC cells lines showed increased expression of FOLR2 mRNA compared with the normal HBE cells (Figure 1A). A549 (P<0.01), NCI-H1299 (P<0.05) and NCI-H1650 (P<0.01) showed the most significant increase in expression of FOLR2 mRNA; the NCI-H460 cells showed expression levels of FOLR2 mRNA that was comparable with the HBE cells.

The FOLR2 protein levels of four NSCLC cell lines, A549, NCI-H1299, NCI-H1650, and NCI-H460, were significantly increased when compared with normal HBE cells (P<0.01) (Figure 1B, 1C). However, because the NCI-H1650 human NSCLC cell lines showed the highest expression of FOLR2 mRNA and FOLR2 protein, this cell line was used for the further experiments, including silencing studies for FOLR2.

Expression of FOLR2 mRNA and FOLR2 protein following transfection with small interfering RNA (siRNA) (siFOLR2) in the human NSCLC cell line, NCI-H1650

To determine the transfection efficiency of FOLR2 in human NSCLC NCI-H1650 cells, both mRNA and protein analysis were performed. Control and NC cells showed no significant difference in mRNA level. The siFOLR2 group showed significantly reduced expression of FOLR2 mRNA and FOLR2 protein compared with the control and NC group (P<0.01) (Figure 2A, 2B).
Silencing of FOLR2 expression (siFOLR2) reduced the cell viability of the human NSCLC cell line, NCI-H1650

To investigate the cell viability of siFOLR2 expression in NCI-H1650 cells, the cell counting kit-8 (CCK-8) assay was performed. As shown in Figure 2C, after 12 hours, the cell viability of the siFOLR2 group had a slight but a non-significant difference when compared with the control or NC groups. After 24 h or 48 h in culture, the siFOLR2 cell viability was significantly decreased compared to the control NCI-H1650 cells (P<0.05) (Figure 2C).

Silencing of FOLR2 expression (siFOLR2) increased cell apoptosis of the human NSCLC cell line, NCI-H1650

The effect of FOLR2 silencing on apoptosis of NCI-H1650 cells was detected by flow cytometry. The rate of cell apoptosis of the siFOLR2 group was significantly increased when compared with the control or NC cells (P<0.01) (Figure 2D). This result indicated that FOLR2 gene silencing could promote NCI-H1650 cell apoptosis.
Figure 3. Silencing of expression of the FOLR2 gene with small interfering RNA (siRNA) affected the expression of cell cycle-associated genes and apoptosis-related genes in NCI-H1650 human non-small cell lung carcinoma (NSCLC) cells. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to assess the expression of mRNA for cyclin D1 (A), p21 (B), p27 (C), in NCI-H1650 human non-small cell lung carcinoma (NSCLC) cells. (D) Western blot was used to detect the protein levels of cyclin D1, p21, and p27 in NCI-H1650 human NSCLC cells. Using qRT-PCR, mRNA expression of Bax (E) and Bcl-2 (F) were assessed in NCI-H1650 human NSCLC cells. (G) Western blot detected the protein levels of Bax and Bcl-2 in NCI-H1650 human NSCLC cells. β-actin was used as an internal control. Data are expressed as the mean ± SD from three independent experiments. (* Compared with control, # compared with NC, */# P<0.05; **/# P<0.01).
Silencing of FOLR2 expression (siFOLR2) arrested the cell cycle of the human NSCLC cell line, NCI-H1650

To investigate the effect on proliferation of siFOLR2 transfected NCI-H1650 cells, the cell cycle was studied using flow cytometry. As shown in Figure 2E, the percentage of cells in the siFOLR2 group showed a significantly increased G1 phase compared with the control or NC group (P<0.05) (Figure 2E). Both the S phase and G2 phase were significantly reduced in siFOLR2 NCI-H1650 cells compared with the control cells (S phase, P<0.05) (G2 phase, P<0.01) (Figure 2E).

Silencing of FOLR2 expression (siFOLR2) affected the expression of cell cycle-associated genes in the human NSCLC cell line, NCI-H1650

To further study how siFOLR2 transfection in NCI-H1650 cells could affect the cell cycle, the expression of cell cycle-associated genes were detected using quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot. Cyclin D1 mRNA expression was significantly reduced in siFOLR2 NCI-H1650 cells compared with the control or NC cells (P<0.01) (Figure 3A). Expression of the mRNA of the cell cycle suppressors, p21...
The result showed high expression of NCI-H1299, NCI-H1650, and NCI-H460 and compared the findings with the protein levels in siFOLR2 NCI-H1650 cells compared with the control or NC cells, cyclin D1 (P<0.05); p21 (P<0.01); p27 (P<0.01) (Figure 3D).

Silencing of FOLR2 expression (siFOLR2) affected the expression of apoptosis-associated genes in the human NSCLC cell line, NCI-H1650

The expression of apoptosis-related genes BAX and Bcl-2 genes were detected using quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot. The result showed that both mRNA and protein level for BAX were significantly increased in siFOLR2 NCI-H1650 cells compared with the control or NC cells (P<0.01) (Figure 3E, 3G). Compared with the control or NC cells, the siFOLR2 group showed significantly reduced levels of expression of Bcl-2 mRNA and protein (P<0.01) (Figure 3F, 3G).

Silencing of FOLR2 expression (siFOLR2) inhibited the AKT/mTOR/S6K1 signaling pathway in the human NSCLC cell line, NCI-H1650

To investigate the molecular mechanism for the effect of siFOLR2 on cell proliferation, the cell cycle, and apoptosis in the human NSCLC cell line, NCI-H1650, the protein levels of AKT, mTOR, and S6K1 signaling were detected by Western blotting. The blots showed that the protein of AKT, mTOR and S6K1 had no clear difference compared with control or NC cells, but the phosphorylation of the three proteins showed significantly decreased expression in siFOLR2 NCI-H1650 cells (P<0.01) (Figure 4). These findings indicated that silencing the expression of the FOLR2 gene in the human NSCLC cell line NCI-H1650 could inhibit the AKT/mTOR/S6K1 signaling pathway.

Discussion

In the USA, and worldwide, lung cancer is the leading cause of cancer death, with non small-cell lung cancer (NSCLC) being the commonest histological type [1]. Studies continue to try to find more effective diagnostic and treatment methods for human NSCLC. The folate receptor gene FOLR2, a member of folate receptor family, has distinct difference with FOLR1 which is expressed in normal tissues and several types of malignancy [27–30].

The findings of the present study demonstrated FOLR2 expression on some human NSCLC cell lines including A549, NCI-H1299, NCI-H1650, and NCI-H460 and compared the findings in a normal human bronchial epithelial (HBE) cell line. The result showed high expression of FOLR2 in NSCLC cell lines compared with normal HBEs. This finding differs from previous studies that have shown that FOLR2 and FR-β were preferentially expressed in tumor-associated macrophages (TAMS) rather than cancer cells [31,32]. However, FOLR2 expression has been previously reported in tumor cells of myelogenous leukemia [15].

In this study, FOLR2 gene silencing (siFOLR2) was performed for NCI-H1650 cells, which resulted in reduced cell proliferation and cell viability, increased cell apoptosis and inhibited the phosphorylation of AKT, mTOR, and S6K1. FOLR2 gene silencing (siFOLR2) in NCI-H1650 cells also affected the cell cycle, with a significantly increased G1 phase and significantly reduced S phase and G2 phase when compared with control cells. Cell cycle-associated genes cyclin D1, p21 and p27, apoptosis-associated genes, BAX and Bcl-2 were measured. Cyclin D1 is a cell-cycle regulator that plays an important role in promoting cell cycle G1/S transformation and is also associated with tumorigenesis [33]. Also, p21 and p27 are two cyclin-dependent kinase (CDK) suppressors responsible for the regulation of the cell cycle [34]. Additionally, p21 is a known cell cycle inhibitor, which binds to cyclin-CDK complexes and proliferating cell nuclear antigen (PCNA), which induces cell cycle arrest at the G1 phase [35,36].

The findings from the present study showed that siFOLR2 could significantly down-regulated cyclin D1 expression, with upregulation of p21 and p27 both at the mRNA and protein levels. This finding was supported by the findings of the cell cycle assay detected by flow cytometry, which showed cell cycle arrest in the G1 phase. The pro-apoptosis gene BAX showed high expression, and the apoptosis suppressor Bcl-2 showed low expression, which was consistent with the findings of the apoptosis rate in siFOLR2 NCI-H1650 cells. These findings support that silencing of FOLR2 expression could inhibit cell proliferation, arrest the cell cycle, and promote cell apoptosis in the human NCI-H1650 NSCLC cell line.

The AKT/mTOR/S6K1 signaling pathway has previously been reported to be a molecular mechanism involved in several human tumors including prostate cancer and breast cancer [37–39]. Phosphorylated AKT can directly activate mTOR, and also can activate mTOR through direct phosphorylation of mTOR Ser2448 sites [40,41]. Activation of AKT/mTOR signaling is associated with occurrence and development of cancer cells [42]. The results of the present study showed that siFOLR2 significantly down-regulated the expression of p-AKT and p-mTOR in NCI-H1650 cells. S6K1 is one of the important substrates of mTOR, existing downstream of AKT/mTOR and acting as an effector of tumor cells proliferation [43,44]. This study showed that silencing the expression of FOLR2 (siFOLR2) also reduced the protein level of S6K1 in NCI-H1650 cells. Therefore, it is possible to interpret from the findings of this study that siFOLR2
could inhibit AKT phosphorylation, which prevented mTOR activation and inhibiting S6K1 phosphorylation, which suppressed cells proliferation and induced apoptosis in the human NSCLC cell line, NCI-H1650, in vitro.

Conclusions

Silencing of the FOLR2 gene could arrest the G1 phase of the cell cycle and induce the cell apoptosis through inhibition of the AKT/mTOR/S6K1 signaling pathway in the human NSCLC cell line, NCI-H1650, in vitro.

Conflict of interest

None.

References:

1. Siegel RL, Miller KD, Jemal A: Cancer Statistics, 2017. Cancer J Clin, 2017; 67(1): 7–30
2. D’Ambrogi SP, Pietanza MC: The molecular pathogenesis of small cell lung cancer. Cancer Biol Ther, 2010; 10(1): 1–10
3. Sun S, Schiller JH, Spinola M, Minna JD: New molecularly targeted therapeutics for NSCLC: the frontiers. J Clin Invest, 2007; 117(10): 2740–50
4. Farid M, Muller DC, Yuan JM et al: Circulating folate, vitamin B6, and methionine in relation to lung cancer risk in the lung cancer cohort consortium (LC3). J Natl Cancer Inst, 2018; 110(1)
5. Brzezinska A, Wniska P, Balinska M: Cellular aspects of folate and antifolate membrane transport. Acta Biochimica Polonica, 2000; 47(3): 735–49
6. Kalli KR, Oberg AL, Keeney GL et al: Folate receptor alpha as a tumor target. Expert Rev Anticancer Ther, 2005; 5(12): 1227–43
7. Ratnam M, Marquardt H, Duhring JL, Freisheim JH: Homologous membrane folate binding proteins in human placenta: Cloning and sequence of a cDNA. Biochemistry, 1989; 28(20): 8249–54
8. Shy F, Wu M, Ross JF et al: Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: Protein characterization and cell type specificity. Biochemistry, 1995; 34(16): 5660–65
9. Tian Y, Wu G, Xing JC et al: A novel splice variant of folate receptor 4 predominantly expressed in regulatory T cells. BMC Immunol, 2012; 13: 30
10. Segi Ei, Low PS: Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev, 2008; 27(4): 655–64
11. van Dam GM, Themelis G, Crane LM et al: Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nature Med, 2011; 17(10): 1315–19
12. O’shannessy DJ, Somers EB, Wang LC et al: Expression of folate receptors in human cells proliferation and induced apoptosis in the human NSCLC cell line, NCI-H1650, in vitro.

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International [CC BY-NC-ND 4.0].
39. Khotskaya YB, Goverdhan A, Shen J et al: S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer. Am J Transl Res, 2014; 6(4): 361–76

40. Rodon J, Dienstmann R, Serra V, Tabernero J: Development of PI3K inhibitors: Lessons learned from early clinical trials. Nat Rev Clin Oncol, 2013; 10(3): 143–53

41. Navé BT, Ouwens M, Withers DJ et al: Mammalian target of rapamycin is a direct target for protein kinase B: Identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J, 1999; 344(Pt 2): 427–31

42. Sun CH, Chang YH, Pan CC: Activation of the PI3K/AKT/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology, 2011; 58(7): 1054–63

43. Hay N, Sonenberg N: Upstream and downstream of mTOR. Genes Dev, 2004; 18(16): 1926–45

44. Hara K, Yonezawa K, Weng QP et al: Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem, 1998; 273(23): 14484–94